New hope for rare lung cancer: drug combo trial opens
Disease control
Not yet recruiting
This study tests a combination of two drugs, lurbinectedin and osimertinib, for a rare lung cancer called transformed small cell lung cancer. It is for people whose cancer changed after initial treatment with osimertinib. The goal is to see if the combo is safe and helps control …
Phase: PHASE1, PHASE2 • Sponsor: Misty Shields • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC